and in the world. The HIV epidemic is concentrated in major urban centres, with high prevalence among the vulnerable population, such as those living on the streets. Studies show that in the last two years, the number of people living with HIV and being on antiretroviral therapy increased about one third, reaching 17.0 million people, 2 million more than the 15 million in 2015. The main goal was to estimate the prevalence of HIV in homeless people.

Methods A cross-sectional study, developed at the Specialised Reference Centre for Homeless People (POP Centre), in the city of Teresina-PI, where participants were recruited using the Snowball technique. The data were collected through a form and a fast HIV test, from August to December/2016. This study comply with the ethical requirements, and had a report of the Research Ethics Committee of the Federal University of Piauí with number 1,755,893.

Results HIV prevalence (n=112) was 7.1%. The age ranged from 19 to over 45 years old, and the prevalence was highest at the age of 25 to 35 years old (2.6%). Of the total number of infected individuals, the participants were single (5.3%), brown (4.5%), had at least one child (2.6%), had their first sexual intercourse between 13 and 19 years old (3.5%), have casual partnership (2.6%) and have no monogamous partnership (3.5%). Regarding to the use of condom with the aforementioned partnership, it was reported as sometimes (0.8%) and (5.3%) reported use of illicit drugs.

Conclusion The prevalence of HIV is high in people living on the street with higher incidence in singles, with early sexual activity, not having a monogamous partnership and use of illicit drugs. It is essential to trace cases in this type of population and control the follow-up of detected cases. In addition, guidance on preventive measures.

LB3.256 SURVEY OF HEPATITIS B VACCINE ISSUE IN HOMELESS PEOPLE IN THE CENTRAL AREA OF A NORTHEAST CAPITAL OF BRAZIL
Rosiane de Lima Brito Magalhães; Vanessa Moura Carvalho de Oliveira; Rômulo Veloso Nunes; Polyanna Maria Oliveira Martins; Marcos André Siqueira de Sousa; Braulio Vieira de Sousa Borges. Universidade Federal Do Piauí, Teresina – PI, Brazil

Introduction The prevalence of hepatitis B is higher in populations at risk, such as people living on the street. This population is more vulnerable to several diseases, such as hepatitis B, which can be prevented by adhering to the three-dose schedule of hepatitis B vaccine. The main goal was to investigate the vaccination situation against hepatitis B in this kind of population.

Methods Cross-sectional study with quantitative approach. The research was developed at the Specialised Reference Centre for Homeless People (POP Centre). Participants were recruited through the Snowball Technique. The data were collected through the application of a form, from September to December 2016. This study was submitted and approved by the Research Ethics Committee of the Federal University of Piauí with the number of report 1,755,893.

Results Of the 58 participants, the majority, 49 (84.5%) were males. The age ranged from 21 to over 50 years old. Regarding sexual behaviour, 7 (12.1%) participants reported feeling same-sex attraction. Only 3 (5.2%) reported having a monogamous partner, and among these, 2 (3.4%) reported not using condoms with the aforementioned partner. Only 11 (19.0%) participants had a vaccine card. Of the total, 35 (60.3%) did not know how to report their vaccination status. Of the doses of hepatitis B vaccine given previously, 3 (5.2%) reported having taken two doses of vaccine. The remainder, 15 (35.9%), had not taken any dose of the vaccine. Only 3 (5.2%) reported having completed the vaccination schedule.

Conclusion Considering the low adherence to the three doses of vaccine against Hepatitis B, it is important to invest in the continuous supply of immunobiological and to expand orientation strategies regarding the importance of the complete vaccination scheme for this population.

1Rudzani Mathebula, 2Lazarus Kuzonza, 3Ramini Kulatrane, 1Tendayi Chakeza. 1National Institute for Communicable Diseases, Johannesburg, South African Republic; 2National Institute of Communicable Diseases, Johannesburg, South African Republic

Introduction The elimination target for congenital syphilis (CS) is <50 cases per 1 000 000 live births. We describe trends of laboratory data for possible early CS across South Africa (SA) and estimate its incidence in infants over a six year period.

Methods We conducted a cross-sectional analysis of laboratory data collected through the National Health Laboratory Service (NHLS) Corporate Data Warehouse (CDW) from 2010 to 2015. The NHLS CDW is a central repository of all laboratory tests performed in all public sector clinical laboratories in South Africa. We defined possible early CS as a positive serum Rapid Plasma Reagen (RPR) result in a child <2 years. Syphilis seropositivity rate was calculated as the number <2 years with a positive RPR test result divided by the total number <2 years tested during this time. Children with multiple RPR tests were counted once during this period. Incidence rate was calculated as the number of infants<1 year who had positive RPR results in a given year divided by the total number of livebirths for that year.

Results Of 84 341<2 years tested during 2010–2015 (92.3% <1 year, 40.7% male), 6357 (7.5%) tested positive. The number of children tested per year ranged from 23 555 in Gauteng Province to 1555 in the Northern Cape. RPR seropositivity in <2 years increased from 6% in 2010 to 9% in 2015 (p-value<0.001). Estimated national annual CS incidence rates in infants increased from 99/100,000 livebirths in 2010 to 119/100,000 livebirths in 2015. Largest increases in incidence rates were KwaZulu-Natal (44-115/100,000 livebirths), Limpopo (10-25/100,000 livebirths), and Mpuamalanga (26-67/100,000 livebirths), while declines were observed in Eastern Cape (278-178/100,000 livebirths), Northern Cape (168-66/100,000 livebirths), and Free State (84-51/100,000 livebirths).

Conclusion Though limited to laboratory results, the analysis shows high incidence possible CS. SA may need to intensify elimination efforts to reach the WHO target. Further clinical and maternal treatment information is needed in order to confirm incidence rates of early CS.
Abstracts

**LB3.258** RATES OF PELVIC INFLAMMATORY DISEASE AND ECTOCYTE PREGNANCY ARE NO LONGER DECLINING: AN ECOLOGICAL ANALYSIS OF AUSTRALIAN HOSPITAL ADMISSIONS AND EMERGENCY PRESENTATION DATA, 2009–2014

1Jane L. Goller, 2Alpaca De Liera, 3Rebecca J. Guy, 4Nicola Lou, 1Basil Donovan, 2Matthew Laws, 1John Kaldor, 1Christopher K. Frear, 1Jane S. Hocking, 1Melbourne School of Population and Global Health, University of Melbourne, Parkville, Australia; 2Kirby Institute, Unsw, Sydney, Australia; 3University of Bern, Bern, Switzerland; 4Central Clinical School, Monash University And Melbourne Sexual Health Centre, Melbourne, Australia

**Introduction** Pelvic inflammatory disease (PID) and ectopic pregnancy (EP) among women are important sequelae of sexually transmissible infections (STIs). We assessed recent trends in these STI-related morbidities in three Australian states (Victoria, New South Wales, Queensland).

**Methods** Hospital admission and emergency presentation PID and EP rates among women 15–44 years were extracted and analysed by residential postcode for 2009–2014 using population and live birth denominators where relevant. Final data were available in 2017. Zero Inflated Poisson (ZIP) models were used to assess variation in rates by year, age, socioeconomic disadvantage and area of residence. A sub-analysis of acute and/or STI-confirmed PID admissions was undertaken.

**Results** Admission and emergency presentation rates respectively per 100,000 women in 2014 were: i) 63.3 (95% CI: 60.8–65.9) and 97.0 (95% CI: 93.9–100.2) for PID; and ii) 107.8 (95% CI: 104.5–111.2) and 96.7 (95% CI: 93.6–99.9) for EP. Of all emergency cases, 68% of PID and 22% of EP were managed without admission. PID admission rates did not change by year, but acute/STI-confirmed PID admissions increased by 40% between 2009 and 2014 (Incidence rate ratio [IRR]: 1.1; 95% CI: 1.1–1.2). Emergency PID rates increased by 30% between 2009 and 2014 (IRR: 1.3; 95% CI: 1.2–1.5). PID admission and emergency rates were highest among women 15–24 years. Population based EP rates increased by 10% in emergency between 2009 and 2014 (IRR: 1.1; 95% CI: 1.1–1.2). EP rates per 1000 live births increased by 8% (IRR: 1.08; 95% CI: 1.06–1.11) for admissions and 27% (IRR: 1.27; 95% CI: 1.21–1.33) for emergency between 2009 and 2014. Increasing disadvantage and remoteness of area tended to be associated with higher PID and EP rates.

**Conclusion** These data show that, for the first time in two decades, STI-related sequelae diagnoses at Australian hospitals are increasing.

**LB3.259** E-STI TESTING AND RESULTS SERVICE: A SINGLE BLIND RANDOMISED CONTROLLED TRIAL

1Emma Wilson, Dr., 2Caroline Fee, 3Tim P Morris, 4Jonathan Syred, Dr. 5Anatole S Menon-Johansson, Dr., 6Melissa J Palmer, 7Sharmini Barnard, 8Emma Rezel, Dr., 9Paula Baraitser, 1London School of Hygiene and Tropical Medicine, London, UK; 2MRC Clinical Trials Unit At University College London, London, UK; 3King’s College London, London, UK; 4Guy’s and St. Thomas’ NHS Foundation Trust, London, UK

**Introduction** STI self-sampling accessed via the internet (e-STI testing) is recommended to expand access to services. There is limited evidence on its effectiveness. This is the first RCT to evaluate an e-STI testing service for chlamydia, gonorrhoea, HIV and syphilis.

**Methods** Single-blind RCT with allocation concealment.

Eligibility: aged 16–30, resident in 2 boroughs of London, having at least one sexual partner in the last 12 months, willing to take an STI test.

Participants were randomly allocated to (1) an e-STI testing service or (2) to a website with signposting to local sexual health clinics.

**Primary outcomes** were: 1) diagnosis of any STI 2) completion of any STI test.

All analyses were intention-to-treat. We used multivariate imputation using chained equations (MICE) for the primary analyses. We explored heterogeneity by age, gender, ethnicity, deprivation, number of sexual partners in the last 12 months, and sexuality.

**Results** 2072 participants were randomised. The response rate was 84%. At 6 weeks, 50.0% of the intervention group completed an STI test compared to 26.6% in the control group (RR 1.87, 95% confidence interval 1.63 to 2.15, p<0.0001). 2.8% of the intervention v 1.4% in the control were diagnosed with an STI (RR 2.10, 95% confidence interval 0.94 to 4.70, p=0.079). The effect on cases treated was 1.1% in the intervention v 0.7% in the control (RR 1.72, 95% confidence interval 0.71 to 4.16, p=0.231).

No heterogeneity was observed in the pre-specified sub group analyses.

Time-to-test was lower in the intervention arm compared to the control arm (28.8 days vs 36.5 days; p<0.0001). No differences were observed for time-to-treatment (83.2 days vs 83.5 days; p=0.51).

Data cleaning and data collection were still underway late 2016.

**Conclusion** E-STI testing increased testing uptake and may yield a small increase in STI diagnoses. Service innovations may be needed so that gains in testing and diagnoses translate into similar gains in cases treated. e-STI testing could be a valuable option in high prevalence contexts where expanding access is priority.

**LB3.260** MULTIDRUG RESISTANT MYCOPLASMA GENITALIUM IN HIV-INFECTED MEN WHO HAVE SEX WITH MEN (MSM) IN THE UNITED STATES

Li Xiao; William M. Geisler, Ken B. Waite, Kristal I. Aaron, Jodie A. Dionne-Odom. University of Alabama at Birmingham, Birmingham, USA

**Introduction** Mycoplasma genitalium (MG) is a common cause of urethritis in men. In the U.S., CDC recommends treatment for MG with azithromycin or moxifloxacin, but treatment success is threatened by increasing resistance to both therapies. Rectal MG infection has been described among MSM, but little is known about rectal MG prevalence and frequency of antibiotic-resistant MG in HIV-infected MSM.

**Methods** We retrospectively evaluated the prevalence of MG infection and antibiotic-resistant MG in 158 HIV-infected MSM who self-collected rectal and urine samples for a study at an HIV clinic in Birmingham, Alabama in 2014–2016. Eligibility criteria included receptive anal intercourse in the past 30 days and no recent antibiotic exposure (except trimethoprimsulfamethoxazole). A real-time PCR assay was used to
detect MG and macrolide resistance by targeting the 23S rRNA gene. Nested PCRs were used to detect mutations in quinolone resistant determination regions in gyrA, gyrB, parC and parE genes.

**Results** MG infection was detected in 27 MSM (17.1%); 18 (11.4%) at the genital site and 9 (5.7%) at the rectal site. The bacterial load ranged from 2–32,700 genome copies/µl. Macrolide resistant MG was detected in 19 men (70.4%), featuring typical 23S rRNA mutations (A2071G or A2072G transitions). One subject with MG had novel gene mutations (G1972T and G2038T) with unknown function. Eight (29.6%) had fluoroquinolone-resistant MG harbouring parC mutations that cause changes in amino acid position 83 (S83I or S83R); 4 of them had an additional P62S mutation in parC and 1 had a F47S mutation in gyrB. Five men (18.5%) had MG with dual macrolide and fluoroquinolone resistance. The prevalence of resistance was similar at rectal and genital sites.

**Conclusion** This is the first U.S. study to document a high frequency of macrolide and fluoroquinolone-resistant MG in HIV-infected MSM at rectal and genital sites. If these resistance mutations are associated with clinical treatment failure, more effective options to treat MG are needed.

**Abstracts**


Preeti Pathela, Kelly Jamison, Sarah Braunstein, Julia Schillinger. New York City Department of Health And Mental Hygiene, Queens, USA

10.1136/sextrans-2017-053264.496

**Introduction** Men-who-have- sex-with-men (MSM) may modify sexual practices to reduce HIV and sexually transmitted infection (STI) risk. HIV pre-exposure prophylaxis (PrEP) may impact risk behaviour and STI acquisition.

**Methods** We matched HIV-negative MSM attending New York City (NYC) sexual health clinics during 2011–2015 to the NYC HIV registry in 01/2017. We used visit-level data to assess trends in condom use during anal sex (consistent, inconsistent, no use; referent period=3 months), overall and by sexual positioning behaviour. We examined associations between condomless (inconsistent/no use) insertive, condomless receptive, and condomless versatile sex and incident HIV or STI (chlamydia/gonorrhoea/early syphilis). We used regression analysis to determine the impact of HIV infection on children of previously seronegative mothers.

**Results** The proportion of visits with reported consistent condom use decreased from 2011–2015 (39% to 31%), p<0.001; inconsistent use increased (48% to 53%), and no condom use was stable (13–14%). There were significant declines in consistent condom use across all positioning categories. From all visits, MSM reported positioning as: 19% condomless insertive, 9% condomless receptive, 37% condomless versatile, and 35% sex with condoms. For 25,216 STI testing visits that yielded 7438 diagnoses, all condomless-positioning categories were associated with incident STI; highest risk was with condomless insertive sex (aOR 1.8, 95% CI 1.6–1.9). For MSM tested for HIV at 9744 visits, condomless receptive (aOR 2.8; 95% CI 1.9–4.1) and condomless versatile sex (aOR 2.2; 95% CI 1.6–2.8) were associated with incident HIV. Black MSM (~25% of MSM) had the highest risk for HIV (41% of 368 new HIV diagnoses).

**Conclusion** We documented increases in condomless sex among a sentinel high risk group prior to and during the PrEP era. Insertive sex, perhaps perceived as a safer strategy, was associated with substantial STI risk when condoms were not consistently used. Assuring PrEP access for black MSM is critical.

**LB3.262 LATE POSTNATAL HIV MOTHER TO CHILD TRANSMISSION THROUGH BREASTFEEDING: ANALYSIS OF INFANT CASES OF PREVIOUSLY SERONEGATIVE MOTHERS INFECTED DURING LACTATION**

Ana Carolina Barcellos, Nathalia Zorze Rossetto, Cristina de Oliveira Rodrigues. Universidade Federal do Paraná, Curitiba – PR, Brazil

10.1136/sextrans-2017-053264.497

**Introduction** Among children, the main postnatal HIV category of exposure is breastfeeding. When acute maternal infection occurs during lactation, the high maternal viral rate results in a higher risk of infant infection. There are few researches showing the impact of HIV infection on children of previously seronegative mothers, who acquire the HIV virus during breastfeeding. To elucidate the importance of this category of exposure, this study aims to evaluate HIV infection in infants assisted by a Paediatric Infectology Service in Brazil, emphasising the cases where vertical transmission occurred lately through breastfeeding.

**Methods** Transversal, analytical and descriptive study, with quantitative and qualitative approach analysing HIV infected patients from 0 to 16 years old. Data was collected during 2016, from charts of children assisted between 2010 and 2015. After previous selection, breastfed children of mothers who had negative HIV testing during pregnancy and/or at birth, had charts analysed in detail.

**Results** From a total of 122 cases, 95% were mother-to-child-transmissions. Between these cases, 11 were considered possible/confirmed late postnatal transmission through breastfeeding. This group characterisation showed that at diagnosis, 72.7% presented significant and/or recurrent symptoms of HIV infection. In 45.4%, mother and child were diagnosed at the same time and 72.7% of mothers were sexually infected.

**Conclusion** There was a significant prevalence of late postnatal transmission through breastfeeding in our sample. Differently from resource limited settings, most countries avoid breastfeeding by HIV infected mothers. Considering cases where women were infected only during lactation, our study highlights a gap in prevention of vertical transmission of HIV. The severity of infant symptoms, the moment of diagnosis and mother’s category of exposure confirm the importance of preventive measures and scientific improvement to reduce postnatal HIV transmission.